



On behalf of Averitas Pharma, please join us for a presentation on:

**QUTENZA®(capsaicin) 8% Topical System:
From Patented Technology and Unique MOA to Clinical Data**

Presented by:

**Zohra M Hussaini MSN, FNP-BC, MBA
University of Kansas Health System**

**Thursday, November 02, 2023 at 6:00 PM
The Capital Grille
4760 Broadway Blvd. Kansas City, MO 64112**

The objectives for the presentation are to:

1. Learn a different way to treat painful diabetic peripheral neuropathy of the feet
2. Review the efficacy and safety of QUTENZA based on Phase 3 study results
3. Feel confident administering a non-systemic, non-opioid, localized treatment

To reserve a seat for the presentation, please register here:

www.pharmethodportal.com/averitas/register

or please RSVP to Brian Reeves via email at

brian.reeves@averitaspharma.com by phone at 816/728-0883.

Program ID: 10575

We look forward to your participation!

Brian Reeves

INDICATION

QUTENZA® (capsaicin) 8% topical system is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) or associated with diabetic peripheral neuropathy (DPN) of the feet.

IMPORTANT SAFETY INFORMATION

Do not dispense QUTENZA to patients for self-administration or handling. Use only on dry, unbroken skin. Only physicians or healthcare professionals are to administer and handle QUTENZA, following the procedures in the label.

Warnings and Precautions

- **Severe Irritation:** Whether applied directly or transferred accidentally from other surfaces, capsaicin can cause severe irritation of eyes, mucous membranes, respiratory tract, and skin to the healthcare professional, patients, and others. Do not use near eyes or mucous membranes, including face and scalp. Take protective measures, including wearing nitrile gloves and not touching items or surfaces that the patient may also touch. Flush irritated mucous membranes or eyes with water and provide supportive medical care

for shortness of breath. Remove affected individuals from the vicinity of QUTENZA. Do not re-expose affected individuals to QUTENZA if respiratory irritation worsens or does not resolve. If skin not intended to be treated comes into contact with QUTENZA, apply Cleansing Gel and then wipe off with dry gauze. Thoroughly clean all areas and items exposed to QUTENZA and dispose of properly. Because aerosolization of capsaicin can occur with rapid removal, administer QUTENZA in a well-ventilated area, and remove gently and slowly, rolling the adhesive side inward.

- **Application-Associated Pain:** Patients may experience substantial procedural pain and burning upon application and following removal of QUTENZA. Prepare to treat acute pain during and following application with local cooling (e.g., ice pack) and/or appropriate analgesic medication.
- **Increase in Blood Pressure:** Transient increases in blood pressure may occur with QUTENZA treatment. Monitor blood pressure during and following treatment procedure and provide support for treatment-related pain. Patients with unstable or poorly controlled hypertension, or a recent history of cardiovascular or cerebrovascular events, may be at an increased risk of adverse cardiovascular effects. Consider these factors prior to initiating QUTENZA treatment.
- **Sensory Function:** Reductions in sensory function (generally minor and temporary) have been reported following administration of QUTENZA. All patients with sensory deficits should be assessed for signs of sensory deterioration or loss prior to each application of QUTENZA. If sensory loss occurs, treatment should be reconsidered.

Adverse Reactions

The most common adverse reactions ($\geq 5\%$ and $>$ control group) in all controlled clinical trials are application site erythema, application site pain, and application site pruritus.

To report **SUSPECTED ADVERSE REACTIONS**, contact Averitas Pharma, Inc. at 1-877-900-6479 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information.

HCPs from the states of Vermont and officials or employees of federal or state agencies or state employees, are strictly prohibited by law from accepting food items or meals of any kind, regardless of value, during this on-site meeting. Additionally, in accordance with Minnesota law, Averitas Pharma may not provide meals that total in aggregate more than \$50.00 per year to any HCP who resides or practices in Minnesota.

This information collected will be used by the company to comply with its legal reporting obligations under applicable state and federal laws, including without limitation, the Physician Payment Sunshine (Open Payments) Act.

**In accordance with Averitas Pharma's Policy on Interactions with Healthcare Professionals and OIG Guidance, Averitas Pharma does not pay for your incidental expenses or any expenses of spouses or guests.
Guests are not allowed to attend the meeting or meal functions.**

This communication is intended for the named recipient only. Please do not forward.

QUTENZA® is a registered trademark of Averitas Pharma, Inc.
© 2023 Averitas Pharma, Inc. All rights reserved.
360 Mt. Kemble Avenue, 3rd FL, Suite 3, Morristown, NJ 07960
QZA-10-21-0035 v3.0 January 2023